News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
157,662 Results
Type
Article (3684)
Company Profile (112)
Press Release (153866)
Section
Business (50044)
Career Advice (99)
Deals (8742)
Drug Delivery (4)
Drug Development (30732)
Employer Resources (13)
FDA (2731)
Job Trends (3436)
News (90914)
Policy (5943)
Tag
Academia (199)
Allergies (18)
Alliances (11373)
Alzheimer's disease (287)
Approvals (2730)
Bankruptcy (49)
Best Places to Work (3013)
Biotechnology (77)
Breast cancer (20)
Cancer (300)
Cardiovascular disease (20)
Career advice (91)
Cell therapy (58)
Clinical research (25735)
Collaboration (77)
Compensation (96)
COVID-19 (367)
C-suite (35)
Data (380)
Diabetes (34)
Diagnostics (422)
Earnings (21356)
Events (31643)
Executive appointments (107)
FDA (2868)
Featured Employer (24)
Funding (66)
Gene therapy (20)
GLP-1 (116)
Government (431)
Healthcare (2071)
Infectious disease (381)
Inflammatory bowel disease (35)
IPO (5321)
Job creations (531)
Job search strategy (86)
Layoffs (32)
Legal (728)
Lung cancer (55)
Manufacturing (37)
Medical device (658)
Medtech (658)
Mergers & acquisitions (3500)
Metabolic disorders (95)
Neuroscience (354)
NextGen Class of 2024 (806)
Non-profit (254)
Northern California (534)
Obesity (45)
Opinion (21)
Patents (18)
People (15468)
Pharmaceutical (34)
Phase I (7605)
Phase II (11738)
Phase III (8445)
Pipeline (142)
Postmarket research (496)
Preclinical (2780)
Radiopharmaceuticals (99)
Rare diseases (46)
Real estate (978)
Regulatory (5057)
Research institute (236)
Schizophrenia (21)
Southern California (461)
Startups (815)
United States (4225)
Vaccines (62)
Date
Today (49)
Last 7 days (421)
Last 30 days (1089)
Last 365 days (11936)
2024 (10509)
2023 (13423)
2022 (15425)
2021 (16993)
2020 (14550)
2019 (9607)
2018 (6851)
2017 (8597)
2016 (7046)
2015 (8865)
2014 (6628)
2013 (4730)
2012 (4719)
2011 (4675)
2010 (4622)
Location
Africa (85)
Asia (11800)
Australia (1333)
California (1139)
Canada (305)
China (113)
Colorado (31)
Connecticut (45)
Delaware (29)
Europe (22431)
Florida (111)
Georgia (30)
Illinois (46)
Indiana (31)
Kansas (45)
Maryland (140)
Massachusetts (946)
Michigan (28)
Minnesota (47)
New Jersey (408)
New York (423)
North Carolina (250)
Northern California (534)
Ohio (42)
Pennsylvania (236)
South America (133)
Southern California (461)
Texas (108)
Utah (18)
Virginia (20)
Washington State (65)
157,662 Results for "paradigm biopharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Syantra completes patent filing for “new paradigm” in early cancer detection
October 31, 2024
·
2 min read
BioMidwest
Paradigm and Altru Health System Expand Patient Access to Clinical Trials for Rural Population
Paradigm announced results from a collaboration with Altru Health System (Altru) to improve the efficiency of its clinical research program and expand the availability of clinical research as a care option for patients spanning 46 locations across a rural catchment area of over 4,000 square miles in North Dakota and Minnesota.
May 29, 2024
·
4 min read
NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC’s Potential as a Disease Modifying Drug
NeuroSense Therapeutics Ltd. reported statistically significant results from the 12-month data analysis of the PARADIGM Phase 2b study evaluating PrimeC in people living with Amyotrophic Lateral Sclerosis.
July 1, 2024
·
8 min read
Press Releases
A new paradigm in electrophysiology: Medtronic receives FDA approval of Affera™ Mapping and Ablation System and Sphere-9™ Catheter
October 25, 2024
·
6 min read
Drug Development
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
Axsome Therapeutics, Inc. announced the first patient has been dosed in the PARADIGM Phase 3 trial of solriamfetol, an investigational treatment for major depressive disorder.
March 19, 2024
·
5 min read
Genetown
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
NeuroSense Therapeutics Ltd. announces lead author Merit Cudkowicz, Chair of Neurology at Massachusetts General Hospital, and Julieanne Dorn Professor of Neurology at Harvard Medical School, will be presenting data from the PARADIGM Phase 2 study of PrimeC during an Emerging Science session (equivalent to Late Breaker) at the American Academy of Neurology Annual Meeting.
April 12, 2024
·
4 min read
Drug Development
Prokarium Achieves Milestone with First Patient Dosing in PARADIGM-1 Non-Muscle Invasive Bladder Cancer Clinical Trial
Prokarium today announces the dosing of the first patient in their PARADIGM-1 Phase I/Ib clinical trial in non-muscle invasive bladder cancer (NMIBC) patients (NCT06181266).
February 7, 2024
·
2 min read
Drug Development
NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients
NeuroSense Therapeutics Ltd. announces new analyses from its Phase 2b PARADIGM clinical trial, demonstrated a statistically significant slowing of disease progression in high-risk ALS patients treated with PrimeC by 43% (p=0.02) as compared to placebo in the pre-specified per protocol (PP) population analysis after 6 months of treatment.
May 7, 2024
·
9 min read
Drug Development
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today reports additional positive data from its six-month double-blind Phase 2b PARADIGM trial of NeuroSense’s lead drug candidate PrimeC for the treatment of amyotrophic lateral sclerosis (“ALS”).
February 21, 2024
·
9 min read
Genetown
Paradigm Completes 40,000th Procedure with the QUICKDRAW MIS Bone Harvester.
Paradigm BioDevices, “The Leader in MIS Bone Graft Harvesting,” is pleased to announce the completion of 40,000 procedures utilizing the QUICKDRAW MIS Bone Grafting System.
October 11, 2023
·
2 min read
1 of 15,767
Next